Identifying Factors Affecting of Cooperation Management between Charities and the Teaching Hospitals of Shahid Beheshti University of Medical Sciences

Objectives: One of the most important issues in the provision of health services in every country is providing the necessary resources for presenting these services. Cooperation between charity organizations and public hospitals is especially important as it can increase charity participation, facilitate public participation in the treatment area and develop hospital units. This study aimed was to identify factors affecting cooperation Management and designing a model of cooperation management between charities and the university hospitals of Shahid Beheshti University of Medical Sciences. Methods: This descriptive-analytical, cross-sectional and applied study was conducted in hospitals of Shahid Beheshti University of Medical Sciences in 2019. The statistical population consisted of 411 people including managers, chiefs and deputies, contracting hospital experts and social workers, managers and lawyers of the university, trustees and managers and charity experts. The research sample consisted of 330 people who were selected through the stratified random sampling method. Data was collected using a researcher-made questionnaire. The SPSS 18 and AMOS software were used to analyze the data. Results: The most effective contract pattern determinant had a path coefficient of 1.177, while the least effective current consumption expenditure determinant had a path coefficient of 0.530. Conclusion: The following steps are ways in which costs related to an inpatient department are guaranteed to be covered by a charity during the term of the contract: defining the criteria for selecting a charity to operate in a hospital, choosing a cooperative method and a contract template, determining the share of capital and current costs, and selecting the department type in the contract. &nbsp

Breast cancer epigenetics: review article

Stable molecular changes during cell division without any change in the sequence of DNA molecules is known as epigenetic. Molecular mechanisms involved in this process, including histone modifications, methylation of DNA, protein complex and RNA antisense. Cancer genome changes happen through a combination of DNA hypermethylation, long-term epigenetic silencing with heterozygosis loss and genomic regions loss. Different combinations of N-terminal’s changes cooperate with histone variants with a specific role in gene regulation. It have led to load a setting histone that determine transcription potential of a particular gene or genomic regions. DNA methylation analysis in genome region using methylation-specific digital karyotyping of normal breast tissue detect gene expression patterns and DNA specific methylation can be found in breast carcinoma too more than 100 genes in breast tumors or cell lines of breast cancer are reported hypermethylated. Important of DNA methylation on cancer has been concentrated CpG islands hypermethylation. Most of the techniques are able to identify hypermethylated areas. Often, methylated genes play important role in cell cycle regulation, apoptosis, metastasis and tissue invasion, angiogenesis and hormonal signaling. Cyclin D2 (CCND2) gene is an important regulator of cell cycle and increased of expression inhibits the transition from G1 to S cell cycle. This gene is frequently methylated in breast cancer and has been proposed as the first event. Other cell cycle regulator is p16ink4A / CDKN2A that methylated in a large number of human cancers, including breast cancer. Another regulator of the proliferation of breast cancer that methylated is tumor suppressor RAR-β cancer that has been found in lobular and ductal carcinoma. Recent studies have showed the role of epigenetic silencing in the pathogenesis of breast cancer in which tumor suppressor genes have been changed by acetylation and DNA deacetylation. Histone deacetylase inhibitors have different roles in cancer cells and could show the ways of new treatment for breast cancer. In this review, various aspects of breast cancer epigenetics and its applications in diagnosis, prediction and treatment are described